MARKET

RLAY

RLAY

Relay Therapeutics, Inc.
NASDAQ
17.41
-0.54
-3.01%
Pre Market: 17.47 +0.06 +0.34% 04:41 10/09 EDT
OPEN
17.71
PREV CLOSE
17.95
HIGH
17.97
LOW
16.87
VOLUME
4.59K
TURNOVER
0
52 WEEK HIGH
21.27
52 WEEK LOW
5.47
MARKET CAP
3.82B
P/E (TTM)
-11.1118
1D
5D
1M
3M
1Y
5Y
1D
Most shorted stocks on Wall Street
Seeking Alpha · 3d ago
Weekly Report: what happened at RLAY last week (0928-1002)?
Weekly Report · 3d ago
Weekly Report: what happened at RLAY last week (0921-0925)?
Weekly Report · 09/28 09:49
Nuvectis’ In-Licensed Cancer Drug Earned Breakthrough Designation in China, and It’s Not Even Their Lead Asset
TipRanks · 09/25 12:30
Crispr Therapeutics: Why AI Giant Anthropic's Discovery Has Rocked Gene Editing
Seeking Alpha · 09/24 18:59
Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX) and Relay Therapeutics (RLAY)
TipRanks · 09/22 17:00
Weekly Report: what happened at RLAY last week (0914-0918)?
Weekly Report · 09/21 09:49
These mid-cap stocks have A+ momentum grades and over 100% YTD growth
Seeking Alpha · 09/17 13:45
More
About RLAY
Relay Therapeutics, Inc. is a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease. The Company's Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company's lead clinical asset, zovegalisib (RLY-2608), is the pan-mutant selective PI3Ka inhibitor to enter clinical development and is currently in a Phase 3 clinical trial (ReDiscover-2) in HR+/HER2- metastatic breast cancer. Zovegalisib is also being investigated in a group of genetic disease indications called PI3Ka-driven vascular anomalies. Its pipeline also includes programs for NRAS-driven solid tumors and Fabry disease.

Webull offers Relay Therapeutics Inc stock information, including NASDAQ: RLAY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RLAY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RLAY stock methods without spending real money on the virtual paper trading platform.